Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

vTv Therapeutics (VTVT) Operating Expenses (2016 - 2025)

Historic Operating Expenses for vTv Therapeutics (VTVT) over the last 12 years, with Q3 2025 value amounting to $10.7 million.

  • vTv Therapeutics' Operating Expenses rose 6444.82% to $10.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.8 million, marking a year-over-year increase of 1935.19%. This contributed to the annual value of $25.2 million for FY2024, which is 119.6% down from last year.
  • vTv Therapeutics' Operating Expenses amounted to $10.7 million in Q3 2025, which was up 6444.82% from $7.7 million recorded in Q2 2025.
  • vTv Therapeutics' Operating Expenses' 5-year high stood at $11.1 million during Q4 2021, with a 5-year trough of $4.0 million in Q2 2022.
  • Its 5-year average for Operating Expenses is $6.6 million, with a median of $6.5 million in 2025.
  • Per our database at Business Quant, vTv Therapeutics' Operating Expenses surged by 14333.55% in 2021 and then plummeted by 4286.74% in 2022.
  • Over the past 5 years, vTv Therapeutics' Operating Expenses (Quarter) stood at $11.1 million in 2021, then crashed by 42.87% to $6.4 million in 2022, then dropped by 25.9% to $4.7 million in 2023, then grew by 4.29% to $4.9 million in 2024, then soared by 117.95% to $10.7 million in 2025.
  • Its last three reported values are $10.7 million in Q3 2025, $7.7 million for Q2 2025, and $6.5 million during Q1 2025.